DrugMapper


Trade Names:	MERCAPTOPURINE PURINETHOL PURIXAN
Synonyms:	6-MERCAPTOPURINE MONOHYDRATE MERCAPTOPURINA MERCAPTOPURINE HYDRATE MERCAPTOPURINUM NSC-755 NSC-759614 PURI-NETHOL PURINETHOL PURIXAN XALUPRINE XALUPRINE (PREVIOUSLY MERCAPTOPURINE NOVA LABORATORIES)
Status:	Approved (1953)
Entry Type:	Small molecule
Molecule Category:	UNKNOWN Prodrug
ATC:	L01BB02
UNII:	E7WED276I5


InChI Key	GLVAUDGFNGKCSF-UHFFFAOYSA-N
Smile	Sc1ncnc2nc[nH]c12
InChI	InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)

Action	Mechanism of Action	Reference
INHIBITOR	Amidophosphoribosyltransferase inhibitor

Mesh Heading	Maximum Phase	Mesh ID	Reference
Precursor Cell Lymphoblastic Leukemia-Lymphoma	4	D054198	ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	4	D054198	ClinicalTrials
Leukemia, Myeloid, Acute	3	D015470	ClinicalTrials
Crohn Disease	3	D003424	ClinicalTrials
Leukemia, Promyelocytic, Acute	3	D015473	ClinicalTrials
Leukemia, Biphenotypic, Acute	3	D015456	ClinicalTrials
Leukemia	3	D007938	ClinicalTrials
Lymphoma	3	D008223	ClinicalTrials
Colitis, Ulcerative	3	D003093	ClinicalTrials
Histiocytosis, Langerhans-Cell	3	D006646	ClinicalTrials
Leukemia, Biphenotypic, Acute	3	D015456	ClinicalTrials
Leukemia, Biphenotypic, Acute	3	D015456	ClinicalTrials
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	3	D054218	ClinicalTrials
Blastic Plasmacytoid Dendritic Cell Neoplasm	2	D000099067	ClinicalTrials
Colitis	2	D003092	ClinicalTrials
Glioblastoma	2	D005909	ClinicalTrials
Astrocytoma	2	D001254	ClinicalTrials
Oligodendroglioma	2	D009837	ClinicalTrials
Glioma	2	D005910	ClinicalTrials
Brain Neoplasms	2	D001932	ClinicalTrials
Burkitt Lymphoma	1	D002051	ClinicalTrials

Level 3

Level 4

Level 5

Level 6

Indication

Mechanism of Action

Primary Target

Target Level

System Organ Classification (SOC)

	Relative Frequency (%)
Blood and lymphatic system disorders	13.86
General disorders and administration site conditions	11.14
Gastrointestinal disorders	9.93
Infections and infestations	9.41
Injury, poisoning and procedural complications	7.26
Investigations	6.11
Metabolism and nutrition disorders	4.85
Respiratory, thoracic and mediastinal disorders	4.52
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	4.03
Hepatobiliary disorders	3.79
Nervous system disorders	3.75
Vascular disorders	3.75
Skin and subcutaneous tissue disorders	3.56
Immune system disorders	2.41
Endocrine disorders	2.18

MERCAPTOPURINE


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70